ConCallIQ
Go Pro
DRREDDY Diversified 30 Apr 2025

Dr. Reddy's Laboratories Limited — Q4 FY25

Dr.

bullish high
Compare with...
Revenue ₹8,506 Cr +20%
EBITDA ₹2,475 Cr +32%
PAT ₹1,594 Cr +22%
EBITDA Margin 29.1% +267bps
Duration
Read Time 1 min read

✓ Verified against BSE filing

Delivery score0%
Due this quarter2
Delivered0
Missed2

Indian management teams deliver on roughly 12% of specific earnings-call promises. A low score does not indicate dishonesty — it reflects how aspirational forward guidance typically is.

Q3 FY25

R&D spend guidance of 8.5%-9% for FY25

Management expects full-year R&D investment to be in the range of 8.5% to 9% of sales.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1
Q3 FY25

SG&A expenses to remain around 28% of sales

Management indicated SG&A as a percentage of sales will stay at current levels (~28%) going forward.

Missed

Current-quarter commentary contains related risk or weakness, so the promise appears not to have been delivered yet.

heuristic_v1